Login Register Cart 0
Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Hexahydrocannabinol Pharmacology, Toxicology, and Analysis: The First Evidence for a Recent New Psychoactive Substance

Author(s): Silvia Graziano, Maria Rosaria Varì, Simona Pichini, Francesco Paolo Busardo*, Tommaso Cassano and Annagiulia Di Trana

Volume 21, Issue 12, 2023

Published on: 19 July, 2023

Page: [2424 - 2430] Pages: 7

DOI: 10.2174/1570159X21666230623104624

Price: $65

Abstract

Background: During the last two years, hexahydrocannabinol (HHC), the hydrogenated derivative of tetrahydrocannabinol has been freely sold by internet websites as a “legal” replacement to THC and cannabis in a range of highly attractive branded and unbranded products, some of which are sold as “legal highs”. Potentially, there could be a large demand for HHC products by individuals in Europe and internationally.

Methods: Studies reporting HHC pharmacology, toxicology and analysis were identified from Pubmed and Scopus databases, and official international organizations’ websites were considered.

Results: HHC showed the effects of the typical cannabinoid on the central nervous system, with lower potency than Δ9-THC. A few studies highlighted that 9(R)-HHC is more potent than 9(S)-HHC. This molecule showed an affinity for cannabinoid receptor CB1 both in vitro and in vivo, suggesting a possible therapeutic effect in several pathologies. However, the affinity for the CB1 receptor suggests a possible addiction potential, inducing the users to misuse it. Since actual intoxication cases have not yet been reported, the HHC harmful potential was not described, probably due to the lack of effective analytical methods to detect HHC in biological matrices. Conversely, different analytical assays were developed and validated to separate HHC epimers in natural and non-natural sources.

Conclusion: Similarly to other NPS, the HHC represents a cheaper alternative to the controlled Δ9-THC. Its monitoring is a crucial challenge for toxicological and forensic purposes. To this concern, it is essential to further investigate HHC to support health providers in the identification of related intoxications.

« Previous Next »
Graphical Abstract

[1]
EMCDDA technical expert meeting on hexahydrocannabinol (HHC) and related cannabinoids. EMCDDA, 2022. Available from:https://www.emcdda.europa.eu/news/2022/emcdda-technical-expert-meeting-hexahydrocannabinol-hhc-and-related-cannabinoids_de
[2]
Casiraghi, G.; Cornia, M.; Casnati, G.; Fava, G.G.; Belicchi, M.F. A one-step highly stereocontrolled synthesis of (–)- and (+)-hexahydrocannabinol and related compounds. J. Chem. Soc. Chem. Commun., 1986, 98(3), 271-273.
[http://dx.doi.org/10.1039/C39860000271]
[3]
Ujváry, I. HHC and related cannabinoids. Med. Cannabis Cannabinoids, 2022, 5, 159-198.
[http://dx.doi.org/10.1159/000527113]
[4]
Adams, R. MARIHUANA. Science, 1940, 92(2380), 115-119.
[http://dx.doi.org/10.1126/science.92.2380.115] [PMID: 17730206]
[5]
Adams, R.; Smith, C.M.; Loewe, S. Tetrahydrocannabinol homologs and analogs with marihuana activity X1. J. Am. Chem. Soc., 1941, 63(7), 1973-1976.
[http://dx.doi.org/10.1021/ja01852a053]
[6]
Lee, Y.R.; Xia, L. Efficient one-pot synthetic approaches for cannabinoid analogues and their application to biologically interesting (−)-hexahydrocannabinol and (+)-hexahydrocannabinol. Tetrahedron Lett., 2008, 49(20), 3283-3287.
[http://dx.doi.org/10.1016/j.tetlet.2008.03.075]
[7]
Maurya, V.; Appayee, C. Enantioselective total synthesis of potent 9β-11-hydroxyhexahydrocannabinol. J. Org. Chem., 2020, 85(2), 1291-1297.
[http://dx.doi.org/10.1021/acs.joc.9b02962] [PMID: 31833372]
[8]
Ujvàry, I. Hexahydrocannabinol: review of the chemistry and pharmacology of an understudied cannabinoid. Med. Cannabis Cannabinoids, 2023, 5(1), 165.
[http://dx.doi.org/10.1159/000527113]
[9]
Hua, T.; Vemuri, K.; Nikas, S.P.; Laprairie, R.B.; Wu, Y.; Qu, L.; Pu, M.; Korde, A.; Jiang, S.; Ho, J.H.; Han, G.W.; Ding, K.; Li, X.; Liu, H.; Hanson, M.A.; Zhao, S.; Bohn, L.M.; Makriyannis, A.; Stevens, R.C.; Liu, Z.J. Crystal structures of agonist-bound human cannabinoid receptor CB1. Nature, 2017, 547(7664), 468-471.
[http://dx.doi.org/10.1038/nature23272] [PMID: 28678776]
[10]
Reggio, P.H.; Greer, K.V.; Cox, S.M. The importance of the orientation of the C9 substituent to cannabinoid activity. J. Med. Chem., 1989, 32(7), 1630-1635.
[http://dx.doi.org/10.1021/jm00127a038] [PMID: 2738895]
[11]
Thapa, D.; Lee, J.S.; Heo, S.W.; Lee, Y.R.; Kang, K.W.; Kwak, M.K.; Choi, H.G.; Kim, J.A. Novel hexahydrocannabinol analogs as potential anti-cancer agents inhibit cell proliferation and tumor angiogenesis. Eur. J. Pharmacol., 2011, 650(1), 64-71.
[http://dx.doi.org/10.1016/j.ejphar.2010.09.073] [PMID: 20950604]
[12]
EMCDDA (2022c), Formal notification of 6a,7,8,9,10,10ahexahydro- 6,6,9-trimethyl-3-pentyl-6H[1]dibenzo[b,d]pyran-1-ol (hexahydrocannabinol; HHC) by Denmark as a new psychoactive substance under the terms of Regulation (EC) No 1920/2006 and Council Framework Decision 2004/757/JHA. EU-EWS-RCS-FN- 2022-0031, EMCDDA, Lisbon, 21 October , 2022. c
[13]
EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) (2009) Understanding the ‘Spice’ phenomenon, Office for Official Publications of the European Communities, Luxembourg. Available from: https://www.emcdda.europa.eu/publications/thematicpapers/understanding-spice-phenomenon_en
[14]
European Monitoring Centre for Drugs and Drug Addiction In: European Drug Report 2022:Trends and Developments, Publications Office of the European Union; , 2022; pp. 1-60. Available from:https://www.emcdda.europa.eu/publications/edr/trends-developments/2022_en
[15]
United Nations Office on Drugs and Crime (UNODC). Global Overview : Drug Demand. World Drug Report 2. Global Overview: Drug Demand Drug Supply; , 2022, p. 107.
[16]
Adams, R.; Loewe, S.; Pease, D.C.; Cain, C.K.; Wearn, R.B.; Baker, R.B.; Wolff, H. Structure of cannabidiol. VIII. Position of the double bonds in cannabidiol. Marihuana activity of tetrahydrocannabinols. J. Am. Chem. Soc., 1940, 62(9), 2566-2567.
[http://dx.doi.org/10.1021/ja01866a510]
[17]
Mechoulam, R.; Lander, N.; Varkony, T.H.; Kimmel, I.; Becker, O.; Ben-Zvi, Z.; Edery, H.; Porath, G. Stereochemical requirements for cannabinoid activity. J. Med. Chem., 1980, 23(10), 1068-1072.
[http://dx.doi.org/10.1021/jm00184a002] [PMID: 7420350]
[18]
Skinner, W.A.; Rackur, G.; Uyeno, E. Structure-activity studies on tetrahydro- and hexahydrocannabinol derivatives. J. Pharm. Sci., 1979, 68(3), 330-332.
[http://dx.doi.org/10.1002/jps.2600680319] [PMID: 423121]
[19]
Consroe, P.; Martin, A.R.; Fish, B.S. Use of a potential rabbit model for structure-behavioral activity studies of cannabinoids. J. Med. Chem., 1982, 25(5), 596-599.
[http://dx.doi.org/10.1021/jm00347a021] [PMID: 7086846]
[20]
Nye, J.S.; Seltzman, H.H.; Pitt, C.G.; Snyder, S.H. High-affinity cannabinoid binding sites in brain membranes labeled with [3H]-5′--trimethylammonium delta 8-tetrahydrocannabinol. J. Pharmacol. Exp. Ther., 1985, 234(3), 784-791.
[PMID: 2993595]
[21]
Vaysse, P.J.; Gardner, E.L.; Zukin, R.S. Modulation of rat brain opioid receptors by cannabinoids. J. Pharmacol. Exp. Ther., 1987, 241(2), 534-539.
[PMID: 3033219]
[22]
Edery, H.; Grunfeld, Y.; Ben-Zvi, Z.; Mechoulam, R. Structural requirements for cannabinoid activity. Ann. N.Y. Acad. Sci., 1971, 191(1 Marijuana), 40-53.
[http://dx.doi.org/10.1111/j.1749-6632.1971.tb13985.x]
[23]
Yan, G.; Yin, D.; Khanolkar, A.D.; Compton, D.R.; Martin, B.R.; Makriyannis, A. Synthesis and pharmacological properties of 11-hydroxy-3-(1′,1′-dimethylheptyl)hexahydrocannabinol: A high-affinity cannabinoid agonist. J. Med. Chem., 1994, 37(16), 2619-2622.
[http://dx.doi.org/10.1021/jm00042a015] [PMID: 8057304]
[24]
Metna-Laurent, M.; Mondésir, M.; Grel, A.; Vallée, M.; Piazza, P.V. Cannabinoid-induced tetrad in mice. Curr. Protoc. Neurosci., 2017, 80, 9.59.1-9.59.10..
[http://dx.doi.org/10.1002/cpns.31] [PMID: 28678398]
[25]
Reggio, P.H.; McGaughey, G.B.; Odear, D.F.; Seltzman, H.H.; Compton, D.R.; Martin, B.R. A rational search for the separation of psychoactivity and analgesia in cannabinoids. Pharmacol. Biochem. Behav., 1991, 40(3), 479-486.
[http://dx.doi.org/10.1016/0091-3057(91)90350-B] [PMID: 1806940]
[26]
Holtzman, D.; Lovell, R.A.; Jaffe, J.H.; Freedman, D.X. 1-delta9-tetrahydrocannabinol: neurochemical and behavioral effects in the mouse. Science, 1969, 163(3874), 1464-1467.
[http://dx.doi.org/10.1126/science.163.3874.1464] [PMID: 5773112]
[27]
Gaoni, Y.; Mechoulam, R.; Gaoni, Y.; Mechoulam, R. Isolation and structure of DELTA.+- tetrahydrocannabinol and other neutral cannabinoids from hashish. J. Am. Chem. Soc., 1971, 93(1), 217-224.
[http://dx.doi.org/10.1021/ja00730a036] [PMID: 5538858]
[28]
Kogan, N.M.; Mechoulam, R. Cannabinoids in health and disease. Dialogues Clin. Neurosci., 2007, 9(4), 413-430.
[http://dx.doi.org/10.31887/DCNS.2007.9.4/nkogan] [PMID: 18286801]
[29]
Matsuda, L.A.; Lolait, S.J.; Brownstein, M.J.; Young, A.C.; Bonner, T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 1990, 346(6284), 561-564.
[http://dx.doi.org/10.1038/346561a0] [PMID: 2165569]
[30]
Munro, S.; Thomas, K.L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature, 1993, 365(6441), 61-65.
[http://dx.doi.org/10.1038/365061a0] [PMID: 7689702]
[31]
Pertwee, R.G. Cannabinoids and the gastrointestinal tract. Gut, 2001, 48(6), 859-867.
[http://dx.doi.org/10.1136/gut.48.6.859] [PMID: 11358910]
[32]
Howlett, A.C. The cannabinoid receptors. Prostaglandins Other Lipid Mediat., 2002, 68-69, 619-631.
[http://dx.doi.org/10.1016/S0090-6980(02)00060-6] [PMID: 12432948]
[33]
Devane, W.A.; Breuer, A.; Sheskin, T.; Jaerbe, T.U.C.; Eisen, M.S.; Mechoulam, R.; Järbe, T.U.C. A novel probe for the cannabinoid receptor. J. Med. Chem., 1992, 35(11), 2065-2069.
[http://dx.doi.org/10.1021/jm00089a018] [PMID: 1317925]
[34]
Jiang, S.; Iliopoulos-Tsoutsouvas, C.; Tong, F.; Brust, C.A.; Keenan, C.M.; Raghav, J.G.; Hua, T.; Wu, S.; Ho, J.H.; Wu, Y.; Grim, T.W.; Zvonok, N.; Thakur, G.A.; Liu, Z.J.; Sharkey, K.A.; Bohn, L.M.; Nikas, S.P.; Makriyannis, A. Novel functionalized cannabinoid receptor probes: Development of exceptionally potent agonists. J. Med. Chem., 2021, 64(7), 3870-3884.
[http://dx.doi.org/10.1021/acs.jmedchem.0c02053] [PMID: 33761251]
[35]
Paronis, C.A. Nikas, S.P.; Shukla, V.G.; Makriyannis, A. Δ(9)-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice. Behav. Pharmacol., 2012, 23(8), 802-805.
[http://dx.doi.org/10.1097/FBP.0b013e32835a7c4d] [PMID: 23075707]
[36]
EMCDDA In: Technical report: Hexahydrocannabinol (HHC) and related substances; 2023. Available from: https://www.emcdda.europa.eu/publications/technical-reports/hhc-and-related-substances_en
[37]
Carney, J.M.; Balster, R.L.; Martin, B.R.; Harris, L.S. Effects of systemic and intraventricular administration of cannabinoids on schedule-controlled responding in the squirrel monkey. J. Pharmacol. Exp. Ther., 1979, 210(3), 399-404.
[PMID: 113528]
[38]
Desai, R.I.; Thakur, G.A.; Vemuri, V.K.; Bajaj, S.; Makriyannis, A.; Bergman, J. Analysis of tolerance and behavioral/physical dependence during chronic CB1 agonist treatment: effects of CB1 agonists, antagonists, and noncannabinoid drugs. J. Pharmacol. Exp. Ther., 2013, 344(2), 319-328.
[http://dx.doi.org/10.1124/jpet.112.198374] [PMID: 23197773]
[39]
Radwan, M.M.; Wanas, A.S.; Gul, W.; Ibrahim, E.A.; ElSohly, M.A. Isolation and characterization of impurities in commercially marketed Δ8-THC products. J. Nat. Prod., 2023, 86(4), 822-829.
[http://dx.doi.org/10.1021/acs.jnatprod.2c01008] [PMID: 36827690]
[40]
Collins, A.C.; Ramirez, G.A.; Ray, K.P. Synthesis and characterization of the diastereomers of HHC and H4CBD. Nat. Prod. Comm., 2023, 18(3)
[http://dx.doi.org/10.1177/1934578X231158910]
[41]
Karin, K.; Holt, A.; Smith, E.R.; Orlowicz, S.; Taylor, A.M.; Prengman, L.; Wolf, C.E.; Williams, G.; Peace, M.R.; Poklis, J.L. Separation and quantitation of natural and unnatural THC isomers and analogues by high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) 52nd Annu Meet Soc Forensic Toxicol Clevel OH, 2022, p. 163.
[42]
Smith, E.R.; Karin, K.N.; Poklis, J.L.; Peace, M.R. (2022), A qualitative analysis of THC isomers and derivatives in e-liquids Poster #12, presented at the SOFT 2022 Annual Meeting in Cleveland, OHOctober 30 - November 4, 2022 Available from:https://soft.memberclicks.net/assets/Programs/2022%20Program%20Book%20for%20Website%20101922.pdf
[43]
Sams, R.A. Analysis of Hexahydrocannabinols: Eliminating Uncertainty in its Identification. 2022. Available from: https://forgehemp.com/wp-content/uploads/2022/03/Analysis-of-Hexahydrocannabinols-280222.pdf
[44]
Stothard, A.I.; Layle, N.K.; Martin, M.J.; Liu, J.; Bassman, J.R.; Williams, J.B.; Hering, K.W.; Diastereomers, H.H.C. Characterization of Hexahydrocannabinol Diastereomers by NMR, HPLC, GC-MS, and TLC, 2020, 19 Available from:https://cdn2.caymanchem.com/cdn/cms/caymanchem/LiteratureCMS/Characterization of HHC Diastereomers.pdf
[45]
Casati, S.; Rota, P.; Bergamaschi, R.F.; Palmisano, E.; La Rocca, P.; Ravelli, A.; Angeli, I.; Minoli, M.; Roda, G.; Orioli, M. Hexahydrocannabinol on the Light Cannabis Market: The Latest “New” Entry. Cannabis Cannabinoid Res., 2022, X(X), can.2022.0253..
[http://dx.doi.org/10.1089/can.2022.0253] [PMID: 364451812]
[46]
Ujváry, I. Hexahydrocannabinol and closely related semi-synthetic cannabinoids: A comprehensive review. Drug Test. Anal., 2023.
[http://dx.doi.org/10.1002/dta.3519] [PMID: 37269160]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy